Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New England Venture Summit to Showcase Matrix-Bio

Published: Monday, December 09, 2013
Last Updated: Monday, December 09, 2013
Bookmark and Share
Matrix-Bio is seeking investment for its colon cancer-monitoring test.

Matrix-Bio, Inc. is a featured startup company at the 8th annual New England Venture Summit on December 11 at the Hilton Boston Dedham. The cancer monitoring test uses the company’s VeraMarker™ metabolite profiling technology platform to detect the recurrence of cancer months and even years earlier than current diagnostics tests.

Sponsored by Young Startup Ventures, the 8th annual New England Venture Summit is the premier industry gathering connecting venture capitalists, angel investors, technology transfer professionals, senior executives of early stage and emerging growth companies, university researchers, and business incubators. The Summit attracts more than 500 attendees seeking investment opportunities and funding.

Matrix-Bio heads into the New England Venture Summit with substantial early stage success. In February, Matrix-Bio signed a global licensing agreement with Quest Diagnostics for the development of a clinical lab-developed blood test using metabolite profiling to detect breast cancer recurrence (BCR). A commercial launch of the BCR test is anticipated in early 2015.

Colon cancer is the most preventable, yet least prevented cancer. It also has a high rate of reccurrence. As part of his pitch, Matrix-Bio CEO Eric Beier will explain how the company’s VeraMarker™ metabolite profiling technology platform identifies the unique metabolite signature of cancer cells in blood serum samples, supporting early, more accurate cancer detection. Matrix-Bio is developing a suite of colon cancer tests, initially focusing on recurrence monitoring. The market for colon cancer monitoring tests is significant: three million CEA tests (the current test which often yields false positives or detects cancer recurrence late) are performed each year with an estimated total market of $450 million.

Matrix-Bio has licensed additional metabolite biomarker technology from the Purdue Research Foundation to evaluate the commercial potential of diagnostic tests for colon, esophageal, liver and pancreatic cancer; liver cancer in hepatitis C patients; and predicting preoperative chemotherapy effectiveness for breast cancer treatment.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Accessing Metabolic Information with Mass Spec
Scientists at the Helmholtz Zentrum München have developed a new mass spectrometry imaging method which, for the first time, makes it possible to analyze hundreds of metabolites in fixed tissue samples.
Improving Tumour Therapy with Nanoparticles
UHN nanoparticle called PEARLs is a promising utilisation of photo-thermal therapy for cancer treatment.
Exosome Research and Quality Control Using ZetaView
Particle Matrix's ZetaView particle characterisation system used by Cell Guidance Systems for exosome research.
Natural Metabolite Can Suppress Inflammation
An international group of scientists from US, Canada, Germany and Russia has revealed a substance produced in humans that can suppress the pro-inflammatory activity of macrophages – specific cells of immune system.
Some Women With PCOS May Have Adrenal Disorder
Researchers at NIH have found that a subgroup of women with PCOS, a leading cause of infertility, may produce excess adrenal hormones.
Making Metabolite Identification More Efficient
Metasense combines the industry's most-comprehensive metabolic transformation prediction with efficient analysis of LC/MS analytical measurements to identify, visualize, and report chemical biotransformations.
Mothers Obesity Could be Passed on in mtDNA
Obesity can predispose offspring in multiple generations to metabolic problems.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Copper is Key in Burning Fat
Berkeley Lab scientist says results could provide new target for obesity research.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!